Table 2.
Comparison of the antimicrobial resistance profiles of Salmonella isolates from 2019–2020 with those from 2017–2018
| Antimicrobial agent | MIC-Break-point (µg/ml) | No. of resistant isolates (%) | |
|---|---|---|---|
| Previous study a) | Current study b) | ||
| 2017–2018 | 2019–2020 | ||
| n = 264 a) | n = 268 b) | ||
| AMP | ≥ 32 | 20 (7.6) | 14 (5.2) |
| CTX | ≥ 4 | 15 (5.7) | 13 (4.8) |
| CFX | ≥ 32 | 2 (0.8) | 0 (0.0) |
| CTF | ≥ 8 | 20 (7.6) | 14 (5.2) |
| OFLX | ≥ 2 | 5 (1.9) | 0 (0.0) #↓ |
| CP | ≥ 32 | 0 (0.0) | 1 (0.4) |
| SM | ≥ 16 | 249 (94.3) | 264 (98.5)#↑ |
| SUL | ≥ 512 | 213 (80.7) | 242 (90.3)#↑ |
| OTC | ≥ 16 | 217 (82.2) | 213 (79.5) |
| KM | ≥ 64 | 77 (29.2) | 77 (28.7) |
AMP ampicillin, CTX cefotaxime, CFX cefoxitin, CTF ceftiofur, OFLX ofloxacin, CP chloramphenicol, SM streptomycin, SUL sulfamethoxazole, OTC oxytetracycline, KM kanamycin
(a)Salmonella isolates cited from Duc et al., 2022 [18]
(b)Salmonella isolates of this study (the n = 268 includes isolates from 2019 to 2020)
#↓ significantly decreased from the previous year (p < 0.05)
#↑ significantly increased from the previous year (p < 0.05)